摘要
目的探讨多西他赛单药节拍化疗一线治疗老年晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法将20例老年晚期NSCLC患者作为节拍组(多西它赛25mg/m^2静脉滴注1h,第1、8、15天给药,每28天为1个周期),另20例为对照组(多西他赛75mg/m^2静脉滴注1h,第1天给药,每3周重复)。比较2组化疗2周期后的近期疗效、生活质量及毒性反应。结果节拍组近期疗效的有效率、临床受益率虽高于对照组,但差异无统计学意义(P〉0.05);节拍组患者化疗后生活质量改善情况优于对照组(P〈0.01),药物毒性反应较对照组轻(P〈0.05或P〈0.01)。结论多西他赛单药节拍化疗治疗老年晚期NSCLC患者安全有效,优于传统治疗方法。
Objective To explore the efficacy and safety of metronomic docetaxel monotherapy to treat advanced non - small cell lung cancer (NSCLC) in elderly patients. Methods Twenty elderly patients with advanced NSCLC were included into a treatment group who received metronomic docetaeel chemotherapy (through one hour of intravenous infusion with 25 mg/m^2 docetacel on Days 1,8 and 15, with a cycle length of 28 days). Meanwhile, another twenty patients were enrolled into a control group and given traditional docetaxel chemotherapy ( through one hour of intravenous infusion with 75 mg/m: docetacel on Day 1, which was repeated every three weeks). After two cycles of treatment, the short - term efficacy, quality of life and toxic reactions were compared between both groups. Results The treatment group presented a higher effective rate and better clinical benefit response (CBR) than the control group, in spite of no statistical difference ( P 〉 0.05 ). After metronomic therapy, the patients reported better quality of life ( P 〈 0.01 ) and less toxic reactions (P 〈 0.05 or P 〈 0.01 ) than those in the control group. Conclusion Metronomic doeetaxel chemotherapy is superior to the traditional regime with respect to its effectiveness and safely when applied to elderly patients with NSCLC.
出处
《徐州医学院学报》
CAS
2014年第10期665-668,共4页
Acta Academiae Medicinae Xuzhou
基金
徐州市科技局立项课题(XZD1-2010)
关键词
节拍化疗
多西他赛
非小细胞肺癌
老年
metronomic chemotherapy
docetaxel
non- small cell lung cancer
elderly patients